SCHEMBL2369908

SCHEMBL2369908

O=C1Cc2ccccc2N=N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
TRPA1 O75762 5/20 0.41
MAOA P21397 2/20 0.38
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
NOS2 P35228 1/20 0.38
CYP2A6 P11509 1/20 0.37
CES1 P23141 2/20 0.35
BCHE P06276 1/20 0.35
AHR P35869 1/20 0.34
PDK2 Q15119 1/20 0.34
HPGD P15428 2/20 0.34
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
CYP19A1 P11511 2/20 0.33
TNF P01375 1/20 0.33
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32
TLR9 Q9NR96 1/20 0.32
MIF P14174 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14566440 0.80 NOS3 (0.50) CYP1A2MAOANOS3NOS1NOS2
SCHEMBL124176 0.79 CYP1A2 (0.44) CYP1A2TRPA1MAOANOS3NOS1
SCHEMBL599843 0.78 CES1 (0.42) CYP1A2TRPA1MAOANOS3NOS1
SCHEMBL7824209 0.77 CYP1A2 (0.48) CYP1A2TRPA1MAOANOS3NOS1
Cyclamic Acid SCHEMBL6788056 0.75 HSP90AA1 (0.37) GAARAB9ASMN1; SMN2
SCHEMBL6223560 0.75 ALDH1A1 (0.34) HPGDPKMTLR9NPC1RAB9A
SCHEMBL19134062 0.73 ALDH1A1 (0.42) HPGDGAA
SCHEMBL5844144 0.72 NOS3 (0.35) CYP1A2TRPA1MAOANOS3NOS1
SCHEMBL207849 0.72 TRPA1 (0.41) CYP1A2TRPA1MAOANOS3NOS1
SCHEMBL10816499 0.71 CYP1A2 (0.52) CYP1A2TRPA1MAOANOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025011623-A1 CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF 上海壹迪生物技术有限公司 2025-01-16 WO claimed
US-20230075693-A1 FLUORESCENT CURABLE DENTAL COMPOSITION AND CURED PRODUCT THEREOF KURARAY NORITAKE DENTAL INC. (JP) 2023-03-09 US claimed
EP-4079280-A1 FLUORESCENT CURABLE DENTAL COMPOSITION AND CURED PRODUCT THEREOF Kuraray Noritake Dental Inc. (JP) 2022-10-26 EP claimed
EP-2398324-B1 PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME (US) 2014-09-03 EP claimed
EP-2398324-A1 PYRAZOLO [4,3-c]CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Merck Sharp & Dohme Corp. (US) 2011-12-28 EP claimed
WO-2010096338-A1 PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME CORP. (US) 2010-08-26 WO claimed
CN-1218472-A Pharmaceutically useful compounds ASTRA PHARMA PROD (GB) 1999-06-02 CN claimed
EP-0187551-A1 Pyrazolo[4,3-c]cinnolin-3-one derivatives, their salts, preparation process, use as medicaments, compositions containing them and intermediate products ROUSSEL-UCLAF (FR) 1986-07-16 EP claimed
CN-121513008-A Pharmaceutical composition of aza-quinolinone derivative, preparation method and application 成都硕德药业有限公司 2026-02-13 CN disclosed
US-20250346573-A1 AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) 2025-11-13 US disclosed
US-20250346573-A1 AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF CHENGDU EASTON BIOPHARMACEUTICALS CO LTD (CN) 2025-11-13 US disclosed
US-12465559-B2 Fluorescent curable dental composition and cured product thereof KURARAY NORITAKE DENTAL INC. (JP) 2025-11-11 US disclosed
EP-4534533-A1 AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) 2025-04-09 EP disclosed
CN-119735558-A Preparation method and intermediate of aza-quinolinone derivative 成都苑东生物制药股份有限公司 2025-04-01 CN disclosed
WO-1987003201-A1 BENZODIAZINONE-PYRIDAZINONE AND HYDROXY-PYRAZOLYL COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES RORER INTERNATIONAL (OVERSEAS) INC. (US) 1987-06-04 WO disclosed
WO-1987003199-A1 HYDROXY AND AMINOTHIAZOLYL-BENZODIAZINONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES RORER INTERNATIONAL (OVERSEAS) INC. (US) 1987-06-04 WO disclosed
EP-0197226-A1 Chemical hybridization agents comprising derivatives of cinnoline-3-carboxylic acids, and their application LAFARGE COPPEE (FR) 1986-10-15 EP disclosed
EP-0187551-A1 Pyrazolo[4,3-c]cinnolin-3-one derivatives, their salts, preparation process, use as medicaments, compositions containing them and intermediate products ROUSSEL-UCLAF (FR) 1986-07-16 EP disclosed
EP-0187551-A1 Pyrazolo[4,3-c]cinnolin-3-one derivatives, their salts, preparation process, use as medicaments, compositions containing them and intermediate products ROUSSEL-UCLAF (FR) 1986-07-16 EP disclosed
US-4198235-A Dye diffusion transfer process employing compounds that release sulfonamide dye providing radicals AGFA-GEVAERT, A.G. (DE) 1980-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12465559-B2 Fluorescent curable dental composition and cured product thereof BRD1, TBCA, BAZ1A CYP1A2 3884/4885TRPA1 303/4885MAOA 1620/4885
US-20250346573-A1 AZAQUINOLINONE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF PARP1, PARP8, PARP11 CYP1A2 516/4885TRPA1 4536/4885MAOA 332/4885
US-20230075693-A1 FLUORESCENT CURABLE DENTAL COMPOSITION AND CURED PRODUCT THEREOF BRD1, TBCA, BAZ1A CYP1A2 3884/4885TRPA1 303/4885MAOA 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.